Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial

NCT04124601 is registered in ClinicalTrials.gov with Johannes Laengle, MD, PhD as lead sponsor.

NCT NCT04124601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04124601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial
Lead sponsor
Johannes Laengle, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2020
Completion date
March 15, 2024
Enrollment
80 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer